Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Fibrosis Model Development Service
Are you currently facing the critical challenge of translating promising preclinical data into successful clinical outcomes for fibrotic diseases? The unpredictability of traditional rodent models often leads to significant delays and failures in the clinical pipeline. Creative Biolabs' NHP Fibrosis Models service helps you de-risk your development programs and streamline the path to the clinic through advanced, physiologically relevant non-human primate models.
Introduction of NHP Fibrosis Models
Chronic liver disease and fibrosis represent a significant global health burden, with limited treatment options. The inherent differences between human and rodent physiology often hinder the successful translation of preclinical findings to clinical trials. NHPs offer an unparalleled solution due to their close genetic, physiological, and immunological similarities to humans. These homologies provide a more accurate and predictive platform for studying the complex mechanisms of fibrosis and evaluating the efficacy and safety of novel therapeutic candidates.
What Our Service Is
Our NHP Fibrosis Models service provides a comprehensive platform for the preclinical evaluation of anti-fibrotic therapies. We offer a range of well-characterized and translationally relevant models designed to accelerate your research. Our services include:
- Model Induction and Validation: We develop models of fibrosis across multiple organ systems, including liver fibrosis (e.g., thioacetamide-induced, dietary models), kidney fibrosis, and pulmonary fibrosis. Each model is validated using a combination of histology, biomarker analysis, and advanced imaging to ensure it accurately mirrors human disease progression.
- Efficacy and Pharmacodynamic Studies: Our platform allowed for the robust evaluation of your drug's ability to halt or reverse fibrosis. We measure key efficacy endpoints and assess pharmacodynamic markers to provide a deep understanding of your compound's mechanism of action.
Why Choose Us?
The high failure rate of anti-fibrotic drugs in clinical trials is a major pain point for biopharmaceutical companies. This often stems from a lack of translational relevance in preclinical models. Creative Biolabs addresses this by providing models that more closely reflect human disease, creating a more predictive research environment. Our services provide value by:
- Mitigating Clinical Risk: Using NHPs allows for the early identification of potential safety and efficacy issues, giving you the confidence to make informed go/no-go decisions before investing in expensive clinical trials.
- Increasing Predictive Power: Our NHP models' superior homology to humans provides a more accurate prediction of clinical outcomes, reducing the risk of unexpected results in Phase I and II trials.
Distributed under Unsplash License, from Unsplash.
Key Benefits of Our Service
Creative Biolabs' NHP Fibrosis Models service is built on a foundation of scientific excellence and a commitment to accelerating your research. We provide distinct advantages that set our platform apart:
- Optimal Response Speed: Our streamlined processes and dedicated NHP resources allow for efficient study execution, ensuring you receive timely results to maintain your project's momentum.
- Extensive NHP Resources: We maintain a large, well-characterized colony of non-human primates, which includes but not limited to Cynomolgus, Rhesus, Marmoset, and African Green Monkey, enabling us to support projects of varying scales and complexities.
- High Customization: Our experienced team collaborates with you to design a study that precisely meets your specific scientific questions, from model selection to endpoint analysis. We offer flexible study designs to accommodate diverse therapeutic modalities.
- In-Depth Reporting: You will receive comprehensive study reports with meticulous detail, including raw data, histological analysis, and expert interpretation. We provide the robust evidence required for successful regulatory submissions.
How Creative Biolabs' NHP Model Development Can Assist Your Project?
Our NHP Fibrosis Models service is designed as a clear, step-by-step workflow to guide your project from concept to conclusion, providing you with actionable data to move your program forward.
01
Required Starting Materials
02
Project Design & Protocol Finalization
03
Model Induction & Validation
04
Treatment and Dosing
05
In-Life Monitoring and Sample Collection
06
Endpoint Analysis
Key Deliverables
Upon completion of your study, Creative Biolabs provides a comprehensive package of deliverables, ensuring you have all the data required for your next steps. These include:
- Detailed Lab Report documenting the entire study, from methods to results.
- A complete raw data package with all recorded in-life and endpoint data.
- Histological slides and high-resolution images of stained tissue sections.
- Expert model annotations and interpretations of key findings.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: How do NHP fibrosis models compare to rodent models for translational studies?
NHP models offer a closer physiological and immunological match to humans, which is crucial for de-risking your project. While rodent models are useful for initial screening, NHP models provide a more predictive platform for evaluating drug efficacy and safety, helping to reduce the risk of clinical trial failures. We're happy to discuss the specific advantages for your project.
Q: Is a full-scale NHP study necessary for my program?
Not always. The decision to use NHP models is often made at a later stage of drug discovery to confirm findings from smaller, earlier-stage studies. We can work with you to determine the most appropriate time and scale for an NHP study, and we're always available to provide consultation on how to integrate our service into your research plan.
Q: What types of fibrotic diseases can your models replicate?
Our platforms are versatile and can be used to model fibrosis across multiple organs, including the liver, lungs, and kidneys. We have established protocols for a range of induction methods and can also develop custom models to meet your specific needs. Please contact us to learn more about our full range of capabilities.
Q: How do you ensure the reproducibility and quality of your models?
Our model development and validation are performed under strict quality controls. We use standardized protocols and a combination of histological, molecular, and imaging-based endpoints to ensure each model is highly reproducible and accurately reflects the human condition. We are committed to providing you with reliable and high-quality data.
Contact Us
Creative Biolabs is your trusted partner in the development of next-generation therapies for fibrotic diseases. Our NHP models offer a powerful, predictive platform to accelerate your research and bring effective treatments to patients sooner. To learn more about how our NHP Fibrosis Models service can benefit your specific project and to request a detailed quote, please contact our team.